Dyslipidemias and stroke prevention: recommendations of the Study Group of Cerebrovascular Diseases of the Spanish Society of Neurology

Objetivo: Actualizar las recomendaciones de la Sociedad Española de Neurología para la prevención del ictus, tanto primaria como secundaria, en pacientes con dislipidemia. Desarrollo: Se ha realizado una revisión sistemática en Pubmed evaluando los principales aspectos relacionados con el manejo de las dislipidemias en la prevención primaria y secundaria del ictus, elaborándose una serie de recomendaciones relacionadas con los mismos. Conclusiones: En prevención primaria se recomienda determinar el riesgo vascular del paciente con el fin de definir los objetivos de LDLc. En prevención secundaria tras un ictus de origen aterotrombótico se recomienda un objetivo de LDLc < 55 mg/dl, mientras que en ictus isquémicos de origen no aterotrombótico, dado que su relación con dislipidemias es incierta, se establecerán los objetivos en función del grupo de riesgo vascular de cada paciente. Tanto en prevención primaria como secundaria las estatinas son los fármacos de primera elección, pudiendo asociarse ezetimiba y/o inhibidores de PCSK9 en aquellos casos que no alcancen los objetivos terapéuticosObjective We present an update of the Spanish Society of Neurology's recommendations for prevention of both primary and secondary stroke in patients with dyslipidaemia. Development We performed a systematic review to evaluate the main aspects of the management of dyslipidaemias in primary and secondary stroke prevention and establish a series of recommendations. Conclusions In primary prevention, the patient's vascular risk should be determined in order to define target values for low-density lipoprotein cholesterol. In secondary prevention after an atherothrombotic stroke, a target value < 55 mg/dL is recommended; in non-atherothombotic ischaemic strokes, given the unclear relationship with dyslipidaemia, target value should be established according to the vascular risk group of each patient. In both primary and secondary prevention, statins are the drugs of first choice, and ezetimibe and/or PCSK9 inhibitors may be added in patients not achieving the target valu

Outcomes from elective colorectal cancer surgery during the SARS-CoV-2 pandemic

This study aimed to describe the change in surgical practice and the impact of SARS-CoV-2 on mortality after surgical resection of colorectal cancer during the initial phases of the SARS-CoV-2 pandemic

The combination astemizole&ndash;gefitinib as a potential therapy for human lung cancer

Mar&iacute;a de Guadalupe Ch&aacute;vez-L&oacute;pez,1 Violeta Z&uacute;&ntilde;iga-Garc&iacute;a,1 Elisabeth Hern&aacute;ndez-Gallegos,1 Eunice Vera,1 Carmen Alexandra Chasiquiza-Anchatu&ntilde;a,1,2 Marco Viteri-Y&aacute;nez,1,2 Janet Sanchez-Ramos,3 Efra&iacute;n Garrido,3 Javier Camacho1 1Department of Pharmacology, Center for Research and Advanced Studies of the National Polytechnic Institute, Mexico City, Mexico; 2Department of Life Sciences and Agriculture, University of the Armed Forces ESPE, Sangolqu&iacute;, Ecuador; 3Department of Genetics and Molecular Biology, Center for Research and Advanced Studies of the National Polytechnic Institute, Mexico City, Mexico Abstract: Lung cancer is a major cause of cancer mortality. Thus, novel therapies are urgently needed. Repositioning of old drugs is gaining great interest in cancer treatment. Astemizole is an antihistamine proposed to be repositioned for cancer therapy. This drug targets several molecules involved in cancer including histamine receptors, ABC transporters and the potassium channels Eag1 and HERG. Astemizole inhibits the proliferation of different cancer cells including those from cervix, breast, leukemia and liver. Gefitinib is widely used to treat lung cancer; however, no response or drug resistance occurs in many cases. Here, we studied the combined effect of astemizole and gefitinib on the proliferation, survival, apoptosis and gene and protein expression of Eag1 channels in the human lung cancer cell lines A549 and NCI-H1975. Cell proliferation and survival were studied by the MTT method and the colony formation assay, respectively; apoptosis was investigated by flow cytometry. Gene expression was assessed by real-time polymerase chain reaction (RT-PCR), and protein expression was studied by Western blot analysis and immunocytochemistry. We obtained the inhibitory concentrations 20 and 50 (IC20 and IC50, respectively) values for each drug from the cell proliferation experiments. Drug combination at their IC20 had a superior effect by reducing cell proliferation and survival in up to 80% and 100%, respectively. The drugs alone did not affect apoptosis of H1975 cells, but the drug combination at their IC20 increased apoptosis roughly four times in comparison to the effect of the drugs alone. Eag1 mRNA levels and protein expression were decreased by the drug combination in A549 cells, and astemizole induced subcellular localization changes of the channel protein in these cells. Our in&nbsp;vitro studies strongly suggest that the combination astemizole&ndash;gefitinib may be a novel and promising therapy for lung cancer patients. Keywords: astemizole, gefitinib, potassium channels, lung cance

"Organización, fragmentación y posibilidades de cambio: la brecha como vacío fértil"

En este trabajo buscamos comprender los complejos procesos de aprendizaje colectivo, y explorar y diseñar herramientas que posibiliten desarrollarlo. De este modo, observamos brechas y fragmentaciones en la red organizativa, que se enquistan en un vacío estéril que impide el flujo y tensión creativa que requieren los procesos de transformación y cambio. Primeramente se explicitan conceptos, seguido de ejemplos de brechas en torno a las cuales venimos trabajando. Finalmente concluimos con una síntesis integradora para abrir nuevos horizontes que nos conduzcan a una articulación compleja de dichas brechas

Jornadas ICT. 2004

Jornadas ICT. 200